Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

A volatile day of trading
Thu, 1 Aug Closing

Indian equity markets had a rather volatile trading session today. While the indices began the day's proceedings on a firm note, subsequent hours saw them oscillate to either side of yesterday's close. The final trading hour saw profit booking taking toll as the indices closed below the dotted line. While the BSE Sensex today closed lower by 28 points, the NSE-Nifty closed lower by 14 points. The BSE Mid Cap and the BSE Small Cap index were not spared either and lost 1% each. Barring banking stocks, losses were seen across sectors.

As regards global markets, most Asian indices closed firm today while European indices have also opened in the green. The rupee was trading at Rs 60.49 to the dollar at the time of writing.

MNC pharma stocks closed mixed today. While Sanofi India and Novartis closed firm, GSK Pharma and Abbott India were out of favour. Sanofi India announced results for the second quarter and half year ended June 2013. Topline grew by 10.9% YoY during the quarter led by 9.6% YoY growth in the pharmaceuticals business and 38.7% YoY growth in other operating income. Operating margins improved by 3.8% to 27.4% for the quarter. This was helped by lower cost of materials and marginal increase in other expenses. Bottomline grew by 26.4% YoY on the back of better operating margins and higher other income. Going forward, MNC pharma players including Sanofi India are most likely to be impacted by the new pricing policy as the domestic market accounts for a larger chunk of overall revenues as compared to their domestic counterparts.

Shree Cement announced results for the quarter and year ended June 2013 (June ending company). Revenues declined marginally by 0.9% YoY during the quarter ended June 2013 owing to poor performance of the cement segment. However, the robust performance of the power sector restricted the decline in overall sales of the company during the quarter. Operating margins contracted by about 680 basis points (6.8%) YoY to 26.7% on account of lower cement realisations. Net profits declined by 19.1% YoY during the quarter as net profit margins contracted from 24.5% in 4QFY12 to 19.6% in 4QFY13. The company's board of directors declared a final dividend of Rs 12 per share for the financial year ended June 2013. The stock closed lower today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "A volatile day of trading". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.